Abstract 3554
Background
The phase 3 SPARTAN study evaluated the efficacy and safety of APA vs placebo (PBO) in men with high-risk nmCRPC. Because dose reductions/interruptions for the management of AEs that occur during treatment can affect drug efficacy, this analysis sought to understand the relationship of APA pharmacokinetic exposure and the primary end point of SPARTAN, MFS.
Methods
1207 pts were randomized in a 2:1 ratio to APA 240 mg/d or PBO. APA levels, and that of its active metabolite N-desmethyl APA (NAPA), were measured by a validated LC/MS/MS assay. APA and NAPA exposures were quantified as the area under the concentration–time curve at steady state (AUC24) at the average daily dose received, up to the MFS event. Exposure levels were evaluated as quartiles or continuous variables. Univariate and multivariate Cox regression models evaluated the relationship between APA/NAPA exposure and MFS and were adjusted by pre-specified stratification factors (prostate-specific antigen doubling time, bone-sparing agent use, locoregional disease status) and other potential prognostic factors (age, ECOG PS).
Results
1206 pts were included in the analysis. AEs led to dose reduction/interruption in 33% vs 19% of APA and PBO pts, respectively, with average daily dose of 225 mg (APA) vs 229 mg (PBO) in pts with dose reduction/interruption. Mean (coefficient of variation [CV]%) PK exposure levels measured as AUC24 for APA and NAPA, respectively, were 117 (24 CV%) μg·h/mL and 155 (17 CV%) μg·h/mL for APA-treated pts without dose reductions/interruptions, and 112 (24 CV%) μg·h/mL and 148 (18 CV%) μg·h/mL for those with dose reductions/interruptions. MFS benefit was similar across the range of APA/NAPA exposures. In univariate and multivariate Cox regression models, no significant differences in the exposure-MFS relationship were observed for APA and NAPA.
Conclusions
240 mg/d APA provided efficacious drug exposure for the majority of pts, including those who required dose reductions/interruptions due to AEs. The MFS benefit was similar across the range of APA exposure. Dose reductions/interruptions due to AEs did not reduce the efficacy of APA.
Clinical trial identification
NCT01946204.
Legal entity responsible for the study
Janssen Research & Development.
Funding
Janssen Research & Development.
Editorial Acknowledgement
Writing assistance was provided by Brian Haas, PhD, of PAREXEL, and was funded by Janssen Global Services, LLC.
Disclosure
M.R. Smith: Grants: Janssen; Personal fees: Janssen, Astellas, Bayer. C. Perez-Ruixo, O. Ackaert, D. Ouellet, C. Chien, M.K. Yu, J-J. Perez-Ruixo: Employee: Janssen Research & Development; Stock owner: Johnson & Johnson. H. Uemura: Personal fees: Janssen, Astellas, Takeda, Sanofi, Bayer, Astra-Zeneca. D. Olmos: Grants: Janssen, Astellas, Bayer, Sanofi, Genentech, Astra-Zeneca, Bayer, outside the submitted work. P.N. Mainwaring: Personal fees: XING Technologies P/L, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche; Grants: Merck; Pending patent: XING Technologies P/L: All other authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract